Shared on 05 Sep 25
With both the Future P/E and Net Profit Margin for Orchid Pharma remaining stable, analysts have kept their consensus price target unchanged at ₹960.00. What's in the News Board meeting scheduled to consider and approve unaudited limited reviewed financial results for Q1 FY2025-26 (standalone and consolidated) on August 12, 2025.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 52%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 49%AnalystConsensusTarget has decreased profit margin from 18.9% to 16.1% and increased future PE multiple from 25.1x to 28.2x.